2001
DOI: 10.1067/msy.2001.117376
|View full text |Cite
|
Sign up to set email alerts
|

The role of caspases in methotrexate-induced gastrointestinal toxicity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
24
0

Year Published

2005
2005
2017
2017

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 43 publications
(25 citation statements)
references
References 18 publications
1
24
0
Order By: Relevance
“…Gastrointestinal side effects often occur in rheumatic patients during oral application of MTX as nausea, abdominal pain, stomatitis and diarrhea (Hoekstra et al 2003). Enterocolitis is the major toxicity of methotrexate-based cancer chemotherapy, which limits its clinical applications (Papaconstantinou et al 2001). Mao et al (1996) showed that administration of lactobacilli, especially L. plantarum, is helpful in reducing the severity of the methotrexate-induced enterocolitis in rats.…”
Section: Discussionmentioning
confidence: 99%
“…Gastrointestinal side effects often occur in rheumatic patients during oral application of MTX as nausea, abdominal pain, stomatitis and diarrhea (Hoekstra et al 2003). Enterocolitis is the major toxicity of methotrexate-based cancer chemotherapy, which limits its clinical applications (Papaconstantinou et al 2001). Mao et al (1996) showed that administration of lactobacilli, especially L. plantarum, is helpful in reducing the severity of the methotrexate-induced enterocolitis in rats.…”
Section: Discussionmentioning
confidence: 99%
“…It also inhibits epithelial proliferation and enterocyte function and increases the risk of gutassociated sepsis due to disruption of the mucosal barrier. Gastrointestinal toxicity is now the major dose-limiting factor for methotrexate administration [141,198]. The toxicity of MTX to the gastrointestinal epithelium is dependent on the duration of cytotoxic exposure rather than the peak levels achieved by the drug.…”
Section: Methotrexate and The Gastrointestinal Tractmentioning
confidence: 99%
“…Methotrexate (MTX), an anti-metabolite inhibiting purine synthesis enzyme dihydrofolate reductase (Papaconstantinou et al, 2001), is commonly used to treat many pediatric cancers including leukemia and solid tumors. The current study characterized cellular and structural damage caused by short-term MTX treatment in the proximal tibial growth plate cartilage, metaphyseal bone and bone marrow, and examined potential effects of supplementary treatment with one clinically used agent (folinic acid (FA)) in protecting the bone growth mechanisms during MTX chemotherapy.…”
mentioning
confidence: 99%